Straits Times Index
3,337.31 -1.63 (-0.05%) S&P 500
5,291.34 +7.94 (+0.15%) Dow
38,711.29 +140.26 (+0.36%) Nasdaq
16,857.05 +28.38 (+0.17%) Bitcoin USD
70,965.47 +2,312.58 (+3.37%) CMC Crypto 200
1,507.40 +33.66 (+2.28%)
ESPR Jan 2026 2.000 call
| Previous close | 1.1000 |
| Open | 1.3000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 2.00 |
| Expiry date | 2026-01-16 |
| Day's range | 1.1000 - 1.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksEsperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
Esperion's (ESPR) Nilemdo & Nustendi get the European Commission's nod for label expansion based on data from the CLEAR Outcomes study.
GlobeNewswireEsperion to Participate in Upcoming June Investor Conferences
ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website. Jefferies Global Healthcare Conference in New York on June 5, 2024, at 4:30 p.m. ET. Goldman Sachs Healthcare Conference in Miami Beach on June 12, 2024, at 8:40 a.m. ET. Live webcasts can be accessed on the investor and media section of the Esperi
- GlobeNewswire
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
– NILEMDO (bempedoic acid), a First-In-Class, Oral Treatment and NUSTENDI (bempedoic Acid / Ezetimibe Fixed-Dose Combination) Receive Label Update Approval from The European Commission as Treatments to Reduce Cardiovascular Risk by Lowering Low-Density Lipoprotein Cholesterol (LDL-C) Levels – – This Makes Bempedoic Acid the First and Only LDL-C Lowering Treatment Indicated for Primary and Secondary Prevention of Cardiovascular Events – – Up To 80% Of Patients Do Not Reach Guideline-Recommended L
